hepatology

News

Gilead to buy liver disease specialist CymaBay for $4.3bn

Gilead Sciences has beefed up its pipeline with an agreement to buy CymaBay Therapeutics and its seladelpar drug for rare liver disease primary biliary cholangitis (PBC),

News

Another NASH setback as Akero’s efruxifermin stumbles

Around this time last year, Akero was riding high on positive phase 2b data for its candidate non-alcoholic steatohepatitis (NASH) therapy, but new data has dented optimis

News

Alfasigma reaches deal to buy Intercept for $800m

After two FDA rejections for non-alcoholic steatohepatitis (NASH) therapy obeticholic acid (OCA), Intercept Pharma has agreed to be taken over by Italian drugmaker Alfasig

News

Eiger wields axe as FDA sets high bar for hepatitis drug

Eiger BioPharmaceuticals has said it will cut staffing numbers by 25% and refocus its R&D activities on metabolic diseases, after the FDA said it would need a new stud

News

Intercept changes course as OCA is rejected for NASH again

Intercept Pharma has conceded defeat in its battle to get obeticholic acid (OCA) approved as a treatment for non-alcoholic steatohepatitis (NASH) after the FDA rejected it

News

FDA panel vote dashes Intercept’s NASH hopes

Intercept Pharma is facing an uphill battle to get FDA approval of its OCA therapy for non-alcoholic steatohepatitis (NASH) once again, after FDA advisors comprehensively

Gilead to buy liver disease specialist CymaBay for $4.3bn

Another NASH setback as Akero’s efruxifermin stumbles

Alfasigma reaches deal to buy Intercept for $800m

Eiger wields axe as FDA sets high bar for hepatitis drug

Intercept changes course as OCA is rejected for NASH again

FDA panel vote dashes Intercept’s NASH hopes

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

hepatology

Editor's Picks